ZA200703313B - Recombinant human T2 RNase and uses thereof - Google Patents

Recombinant human T2 RNase and uses thereof

Info

Publication number
ZA200703313B
ZA200703313B ZA200703313A ZA200703313A ZA200703313B ZA 200703313 B ZA200703313 B ZA 200703313B ZA 200703313 A ZA200703313 A ZA 200703313A ZA 200703313 A ZA200703313 A ZA 200703313A ZA 200703313 B ZA200703313 B ZA 200703313B
Authority
ZA
South Africa
Prior art keywords
rnase
recombinant human
recombinant
human
Prior art date
Application number
ZA200703313A
Other languages
English (en)
Inventor
Roiz Levava
Schwartz Betty
Smimoff Patricia
Shoseyov Oded
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of ZA200703313B publication Critical patent/ZA200703313B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
ZA200703313A 2004-09-29 2007-04-23 Recombinant human T2 RNase and uses thereof ZA200703313B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61370204P 2004-09-29 2004-09-29

Publications (1)

Publication Number Publication Date
ZA200703313B true ZA200703313B (en) 2008-09-25

Family

ID=36119279

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703313A ZA200703313B (en) 2004-09-29 2007-04-23 Recombinant human T2 RNase and uses thereof

Country Status (9)

Country Link
US (1) US8039240B2 (enExample)
EP (1) EP1805319B1 (enExample)
JP (1) JP5069562B2 (enExample)
AU (1) AU2005288527B9 (enExample)
BR (1) BRPI0516302A (enExample)
CA (1) CA2582041C (enExample)
ES (1) ES2524601T3 (enExample)
WO (1) WO2006035439A2 (enExample)
ZA (1) ZA200703313B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808346B2 (ja) * 1999-08-30 2011-11-02 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 哺乳類細胞の増殖を阻害する方法および組成物
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
ATE548621T1 (de) * 2006-08-01 2012-03-15 Jscd Holding L P Verbessertes trocknungssystem
AU2009309277A1 (en) * 2008-10-30 2010-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Efficient expression of truncated human RNASET2 in E. Coli
WO2011084995A2 (en) * 2010-01-05 2011-07-14 Stratasys, Inc. Support cleaning system
CN110237447B (zh) 2013-09-27 2021-11-02 梅维昂医疗系统股份有限公司 粒子治疗系统
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US20160340659A1 (en) 2014-01-30 2016-11-24 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
JP7059245B2 (ja) 2016-07-08 2022-04-25 メビオン・メディカル・システムズ・インコーポレーテッド 治療計画の決定
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
EP3645111B1 (en) 2017-06-30 2025-04-23 Mevion Medical Systems, Inc. Configurable collimator controlled using linear motors
WO2020112890A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
JP7311620B2 (ja) 2019-03-08 2023-07-19 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのコリメータおよびエネルギーデグレーダ

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5786457A (en) 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1998039446A2 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
AU2095299A (en) * 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
JP4808346B2 (ja) 1999-08-30 2011-11-02 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 哺乳類細胞の増殖を阻害する方法および組成物
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
KR100677108B1 (ko) 2003-06-12 2007-02-01 삼성전자주식회사 정보 저장매체

Also Published As

Publication number Publication date
EP1805319A4 (en) 2009-12-16
JP5069562B2 (ja) 2012-11-07
CA2582041A1 (en) 2006-04-06
ES2524601T3 (es) 2014-12-10
WO2006035439A2 (en) 2006-04-06
EP1805319A2 (en) 2007-07-11
JP2008514224A (ja) 2008-05-08
US20080131419A1 (en) 2008-06-05
AU2005288527B9 (en) 2011-07-28
BRPI0516302A (pt) 2008-09-02
EP1805319B1 (en) 2014-09-03
AU2005288527B2 (en) 2011-02-03
AU2005288527A1 (en) 2006-04-06
HK1100329A1 (en) 2007-09-14
WO2006035439A3 (en) 2007-06-28
CA2582041C (en) 2015-08-04
US8039240B2 (en) 2011-10-18

Similar Documents

Publication Publication Date Title
ZA200703313B (en) Recombinant human T2 RNase and uses thereof
IL179300A0 (en) Novel-antigen-binding polypeptides and their uses
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
IL182498A0 (en) Therapeutic furopyrimidines and thienopyrimidines
EP1824796A4 (en) PROTEIN SKELETONS AND USES THEREOF
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
PT1673460E (pt) Vacinas recombinantes e suas utilizações
EP1716802A4 (en) ENDOSCOPE AND ENDOSCOPE SYSTEM
IL179497A0 (en) Carboranylporphyrins and uses thereof
GB0417345D0 (en) Substituted organopolysiloxanes and uses thereof
EP1838288A4 (en) THERAPEUTIC MATERIALS AND METHODS
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
GB0417344D0 (en) Substituted organopolysiloxanes and use thereof
ZA200606216B (en) Modified human interferon polypeptides and their uses
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0309064D0 (en) Modified peptides and their uses
SG122903A1 (en) Therapeutic peptides and method
GB0407382D0 (en) Therapeutic methods and means
EP1824978A4 (en) HCV-F PROTEIN AND USES THEREOF
GB0318546D0 (en) Quinoxalinones and their use
IL185575A0 (en) Benzoxazocines and their therapeutic use
IL182323A (en) Recombinant human t2 rnase and uses thereof
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses
EP1838728A4 (en) HUMAN PROTOONKOGEN AND THE CODED PROTEIN